Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Rhea-AI Summary
Lucid Diagnostics (NASDAQ: LUCD) closed an underwritten registered direct offering of 18,000,000 common shares at $1.00 per share, generating approximately $18 million in gross proceeds on April 24, 2026.
The offering was anchored by a $15 million investment from a fundamental institutional investor with support from a large existing shareholder. Net proceeds are intended for working capital and general corporate purposes.
AI-generated analysis. Not financial advice.
Positive
- $18.0M gross proceeds from offering
- $15.0M anchor investment from institutional investor
- Proceeds designated for working capital and general corporate purposes
Negative
- Issued 18,000,000 new common shares at $1.00 (potential dilution)
- Gross proceeds reduced by underwriting discounts, commissions, and offering expenses
News Market Reaction – LUCD
On the day this news was published, LUCD declined 1.83%, reflecting a mild negative market reaction. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $192.87M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LUCD fell 16.79% while only one peer (SERA) appeared on momentum scans, down 8.31%, suggesting a LUCD-specific reaction rather than a broad medical devices move.
Previous Offering Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 23 | Underwritten offering pricing | Negative | -16.8% | Priced 18,000,000-share underwritten registered direct offering at $1.00 per share. |
| Sep 11 | Offering closing | Negative | +4.9% | Closed public offering of 28,750,000 shares at $1.00, raising $26.9M net. |
| Sep 10 | Offering pricing | Negative | -19.7% | Priced 25M-share public offering at $1.00 with 3.75M-share option. |
| Sep 09 | Offering announcement | Negative | -19.7% | Announced proposed underwritten public offering under effective S-3 shelf. |
| Apr 11 | Offering closing | Negative | -6.4% | Closed $16.1M net public offering of 14,375,000 shares at $1.20. |
Offering-related headlines for LUCD have typically coincided with negative price moves, averaging -11.53%, with only one past deal showing a positive next-day reaction.
Recent history shows Lucid repeatedly accessing equity markets via underwritten and public offerings, often under its shelf registration. Prior offerings on Sep 9–11, 2025 and Apr 11, 2025 produced mixed but mostly negative price reactions, while the Apr 23, 2026 underwritten offering pricing led to a -16.79% move. Today’s closing announcement under the same program fits this pattern of capital-raising news coinciding with share-price pressure.
Historical Comparison
In the past 12 months, LUCD has issued multiple common stock offerings, averaging a -11.53% next-day move. Today’s closing of the $18M underwritten deal continues that established pattern of equity raises under its shelf.
Lucid has repeatedly used shelf-based common stock offerings and related supplements from 2025–2026 to fund operations, moving from proposed to priced and then closed transactions.
Regulatory & Risk Context
An effective S-3/A shelf filed on Mar 25, 2026 permits Lucid to offer up to $175,000,000 in various securities, including an ATM program of up to $25,000,000 and incorporation of $50,000,000 of unsold prior securities. The current 18,000,000-share underwritten offering uses this shelf, as reflected by recent 424B5 supplements.
Market Pulse Summary
This announcement confirms the closing of Lucid’s underwritten registered direct sale of 18,000,000 shares at $1.00, raising about $18 million in gross proceeds for working capital and general corporate purposes. It follows earlier pricing news under the company’s effective Form S-3 shelf. Historically, Lucid has relied on repeated common stock offerings and an ATM program, so investors may watch future use of its $175,000,000 shelf capacity and any additional equity issuance activity.
Key Terms
underwritten registered direct offering financial
shelf registration statement regulatory
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. Not financial advice.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately
Canaccord Genuity LLC and BTIG, LLC acted as joint bookrunners for the offering.
The securities were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-291981) declared effective by the Securities and Exchange Commission on March 26, 2026. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained from Canaccord Genuity LLC, Attn: Syndication Department, 1 Post Office Square, 30th Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-announces-closing-of-18-million-underwritten-offering-of-common-stock-302753005.html
SOURCE Lucid Diagnostics